MCM
MYGN icon

MAI Capital Management’s Myriad Genetics MYGN Stock Holding History

MAI Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,494
Closed -$6.72K – 3730
2026
Q1 		$6.72K Buy
1,494
+1,445
+2,949% +$7.53K ﹤0.01% 3361
2025
Q4 		$302 Buy
+49
New +$355 ﹤0.01% 3964
2025
Q3 		– Sell
-130
Closed -$691 – 4022
2025
Q2 		$691 Buy
+130
New +$768 ﹤0.01% 3710

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

MAI Capital Management's MYGN Position: Q2 2026 in Review

MAI Capital Management sold out of Myriad Genetics (MYGN) in Q2 2026, closing a stake of 1,494 shares — an estimated $6.72K sold.

MAI Capital Management first reported a position in MYGN in Q2 2025 and held it in 3 quarters. The position peaked at $6.72K in Q1 2026. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • MAI Capital Management reported no remaining Myriad Genetics position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 1,494 Myriad Genetics shares in Q2 2026, an estimated $6.72K.
  • MAI Capital Management first reported a position in Myriad Genetics in Q2 2025 and held it in 3 quarters.
  • MAI Capital Management's Myriad Genetics position peaked at $6.72K in Q1 2026.
  • 196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.